Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"Progression-Free Survival (PFS)"”.
-
Ependymal tumours in childhood: outcomes and prognostic factors
… chemotherapy. RESULTS: The 5-year overall survival (OS) was 63,3 % (median follow up of 46 months). The 5 year progression free survival (PFS) was 50,70%. Seventeen (33,3%) patients experienced treatment failure, of which 13 (76,5%) represented local failure. The median time to first …
-
Advanced breast cancer: A retrospective review comparing two palliative radiotherapy protocols used at Groote Schuur Hospital between 2010 and 2013
… evaluate and compare the loco-regional progression free survival (PFS), overall survival (OS) and acute effects of the two breast palliative regimes used in patients with locally advanced or metastatic breast cancer between 2010 and 2013 in a single institution. Methods: Compliance to …
-
Surrogate endpoints of survival in metastatic carcinoma
… in place of the direct endpoint of overall survival (OS) could theoretically shorten the duration of RCTs and minimise the exposure of patients to ineffective or toxic treatments (2, 3). This thesis examined the relationship between surrogate endpoints and OS in metastatic colorectal cancer …
-
University of Washington/Seattle Cancer Care Alliance Experience with Single Agent Ipilimumab in Advanced Unresectable/Metastatic Melanoma
… treatment ever to be associatedwith improved survival in a phase III clinical trial of patients with metastatic melanoma and was approved by the US Food and Drug Administration (FDA) in 2011. However, the response rates with ipilimumab are low (~10%) and toxicities considerable. The optimal …
-
Multifokaler Progress von Glioblastoma Multiforme nach Therapie mit Tumor Treating Fields
… Sekundäre Endpunkte waren das Overall Survival (OS) und Progression-Free Survival (PFS) der Behandlungsarme im Vergleich, OS und PFS in Abhängigkeit vom MGMT-Methylierungsstatus sowie die Auswirkungen des Metastasierungsmusters auf das OS. Ergebnisse: In beiden Gruppen traten …
-
Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor
… localized disease, with reported 10-year overall survival rates of 54-89% after complete surgical resection. However, for the approximately 20% of HPC/SFT patients who eventually develop local recurrences and/or distant metastases, options for effective treatment are limited and are poorly …
-
Clinical and Therapeutic Significance of Obesity In Melanoma
… of body mass index (BMI) with overall survival (OS) and progression-free survival (PFS) was studied in independent cohorts of >1900 MM patients treated with targeted therapy [dabrafenib and trametinib (D+T) and vemurafenib and cobimetinib], immunotherapy [ipilimumab and …
-
Characterising Heterogeneity of Glioblastoma using Multi-parametric Magnetic Resonance Imaging
… anisotropic diffusion was associated with progression-free survival (PFS, hazard ratio [HR] = 1.08, P < 0.001) and overall survival (OS, HR = 1.36, P < 0.001) in multivariate models. II. Using a thresholding method, two low perfusion compartments were identified, which displayed hypoxic and …
-
Low grade gliomas treated at the University of Cape Town Academic Hospital complex: 2001-2017
… children are low grade gliomas (LGG). Long-term survival rates are high with a slow, progressive course. Tumour location and extent of resection affect outcome. Adjuvant therapy has an important role. Rationale: This study evaluated the demographic data of our patient population, the …
-
The impact of cholesterol and its metabolites on the ovarian tumor microenvironment and cancer progression
… to be clinically important for ovarian cancer survival, highlighting it and its metabolism as potential therapeutic targets for improving the lifespan of patients. In a cohort of 153 patients, we found high total, LDL or non-HDL cholesterol was associated with high tumor grade, which in turn …
-
Challenges facing clinical trial design in oncology
… (ii) the clinical relevance and validity of survival endpoints; (iii) effective integration of quality of life (QOL) tools; and (iv) the feasibility and safety of correlative tests. The results of the individual projects are summarised herein. Results: A systematic review of 166 phase III …
-
Clinical Outcome and Prognostic Factors in Borderline Ovarian Tumors and Invasive Ovarian Carcinomas in Western Sweden
… describe best clinical care in order to improve survival. In a prospectively collected, data-based quality register at the Regional Oncological Centre, all cases of borderline ovarian tumors (BOT) and epithelial ovarian cancer (EOC) from 1993 to 2005 were recorded. Data concerning age, stage, …
-
Κλινική Αξιολόγηση της Λιποσωμιακής Δοξορουβικίνης
… επιβίωση (OS), επιβίωση χωρίς εξέλιξη της νόσου (Progression Free Survival - PFS), επιβίωση χωρίς υποτροπή (Disease Free Survival -DFS), διάμεση επιβίωση (Median Survival), ποσοστό επιβίωσης (Survival Rate) για συγκεκριμένα χρονικά διαστήματα (δεικτών επιβίωσης, εξέλιξης της νόσου) και τα ποσοστά …
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… the clinical management of melanoma, but durable survival benefit is only seen in a minority of patients. The use of these very expensive systemic therapies on all appropriate patients also poses a high economic burden on health systems across numerous countries. Currently, surveillance for …
-
Περιτοναϊκή νόσος και ασκίτης στον καρκίνο ωοθηκών. Ο ρόλος του κυτταρομειωτικού χειρουργείου, της HIPEC και της PIPAC
… βελτίωση τόσο της συνολικής επιβίωσης (overall survival – OS) όσο και της επιβίωσης χωρίς πρόοδο νόσου (progression-free survival – PFS). Ο δείκτης περιτοναϊκής καρκινωμάτωσης (Peritoneal Cancer Index – PCI) χρησιμοποιείται ευρέως για την εκτίμηση της έκτασης της περιτοναϊκής νόσου και τη …
-
Unraveling Host-Gut Microbiota Dialogue and Its Impact On Response to Immune Checkpoint Blockade
… decreased microbiome diversity, and shortened progression-free survival (PFS). These findings were recapitulated in preclinical mouse models designed to reflect patient fiber intake and probiotic use. Across these two tumor models, we show that dietary and lifestyle factors can negatively …